Delaware | 001-34637 | 20-1852016 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
25801 Industrial Boulevard, Suite B, Hayward, California | 94545 | |
(Address of principal executive offices) | (Zip Code) |
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 | Results of Operations and Financial Condition. |
Item 9.01 | Financial Statements and Exhibits. |
Exhibit No. | Description | |
99.1
|
Press Release, dated May 6, 2010 |
2
Date: May 6, 2010 | Anthera Pharmaceuticals, Inc. |
|||
By: | /s/ Christopher P. Lowe | |||
Christopher P. Lowe | ||||
Chief Financial Officer and Vice President of Administration |
Exhibit No. | Description | |
99.1
|
Press Release, dated May 6, 2010 |